Researchers have rallied round a promising molecule for rescuing dying nerves. But getting it into the brain remains a daunting challenge, finds Brian Vastag.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Airaksinen, M. S. & Saarma, M. Nature Rev. Neurosci. 3, 383-394 (2002).
Gill, S. S. et al. Nature Med. 9, 589-595 (2003).
Love, S. et al. Nature Med. 11, 703-704 (2005).
Pardridge, W. M., Kang, Y. S., Buciak, J. L. & Yang, J. Pharm. Res. 12, 807-816 (1995).
Pardridge, W. M. & Boado, R. J. Pharm. Res. 26, 2227-2236 (2009).
Brian Vastag is a freelance reporter in Washington DC.
About this article
Cite this article
Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010). https://doi.org/10.1038/466916a
This article is cited by
Journal of Cell Communication and Signaling (2023)
Journal of Materials Science: Materials in Medicine (2018)
Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
Drugs & Aging (2014)
Nature Reviews Neuroscience (2011)